m*********3
发帖数: 1425 | 1 mAb is better, but nowadays the competition is very high for big pharma, too
many candidates and/or strong connections from big boss. |
|
d***d
发帖数: 335 | 2 大家好 我现在才意识到我原来不喜欢做工程 也不适合做工程 我从小就很想当老师 所
以现在想往教育方面转 有些问题不是很清楚 要请教一下
1.Engineering 工程硕士毕业 有办法能在college教书么？说实话我挺想去大学教书的
稍微轻松些嘛 但是又不想读博士 是不是没有博士的话就没啥机会在大学教书？
2.我目前身份是 H1， 不知道转去教书 是不是身份方面会没有着落 我听说好像不给办
的很多 我想问问 MICHIGAN州是个什么样的情况 因为我立志在U MICHIGAN读书 一方面
因为GG在那附近工作 一方面U M排名好像蛮好
3.有在U MICHIGAN 现在在读的么？我看他们有个master of education of
certification 是一年的program 毕业后给学位和certificate 大家觉得这个怎么样?
它们还有一个是education policy administration and MAB 双学位的课程 是2年半到
3年的 不知道大家觉得这个又怎么样
最后 我实在是对美国的education整体都不了解 最近才开始恶补 想赶紧转 所以任 |
|
n******p
发帖数: 144 | 3 Mab-related , not design都有什莫offer? |
|
U******m
发帖数: 423 | 4 CD28抗体的悲剧也提醒我们，Genetech的成功的确有其幸运成分。现在很多mAb已经发
现了毒妇作用。 |
|
U******m
发帖数: 423 | 5 CD28抗体的悲剧也提醒我们，Genetech的成功的确有其幸运成分。现在很多mAb已经发
现了毒副作用。 |
|
O*******f
发帖数: 926 | 6
个问题
peptomimetics
many examples of mAb as drugs, and many examples of peptide/analogues as
drugs. |
|
r***o
发帖数: 162 | 7 your first statement: No, mAb can be iv, sc or im. |
|
m******l
发帖数: 7 | 8 不知道你的结果可靠不可靠，你还change buffer，有没有丢掉MAb?
从你的描述来看，你对药厂的运作是绝对外行
antibody
as |
|
l*****k
发帖数: 587 | 9 I guess you can wait for certain patent expiration, then make
mab in China...
7 |
|
k******n
发帖数: 133 | 10 Try to do some antibody related work. Almost all protein therapeutics are
mAbs and EPOs. If you have done some antibody engineering, you have much
better chance to get into a biotech.
。。 |
|
E****e
发帖数: 315 | 11 大家觉得除了mab外,在不久的将来什么分子会比较有前途? |
|
b*******e
发帖数: 724 | 12 小分子药的局限性很大,毒性,DMPK是老大难了,做来做去就是这些问题.现在恐怕只有
ONOCOLOGY做小分子还行.大分子也有大分子的问题,毕竟大部分的MAB都是在MEMBRANE上
作用,TARGET有限.另外IMMUNOGENICITY也是个不可忽视的问题. |
|
A*N
发帖数: 1128 | 13 hi Jane,
Would you mind to expound more details about the positions/possibilities in
biopharmaceuticals and CRO, particularly therapeutical proteins (mAbs), in
China?
Thanks |
|
N******o
发帖数: 25 | 14 I guess it's OK to have different gene sequence, but final protein sequence
has to be identical, as FDA mentioned. Minor mofification generally referers
to post-translation modification, including glycosylation, C-terminal Lys
truncation for mAb. FDA does gives small rooms for those known modifications
, especially glycosylation. Those have to be justifitable based on bioassay,
preclinical, even clinical data.
Overall, I believe no sequence variation acceptable in term of biosimilar.
different
... 阅读全帖 |
|
b*******e
发帖数: 724 | 15 短期内内是个不错的公司.但他们公司从长远来讲在TECHNOLOGY上面的局限性比较大.因
为主要是小分子,ANTI VIRAL DRUG.这个市场在SHRINK,尤其是HCV,过了2020就没啥
REVENUE了.GENENTECH相对来讲,是INDUSTY里面技术最全面的.MAB,ADC, BISPECIFIC,小
分子都做的不错,长期的发展回更好些. |
|
E***n
发帖数: 308 | 16 not uncommon in non-Mab novel molecules. |
|
E***n
发帖数: 308 | 17 not uncommon in non-Mab novel molecules. |
|
l******g
发帖数: 1623 | 18 你可以写信去生产MAb的药厂问问，他们会告诉你怎么要到用于研究的样品。 |
|
f*********e
发帖数: 1144 | 19
---have been doing some reading lately. you are exactly right. SFDA treats
whatever biologics as a new molecule, very actively help fund lots local
firm to reformulate mAb drugs, so called" green channel" :)
developed
---cGMP standard facility have been invested, maybe a sign SFDA is catching
up to set regulations on production
---biosimilar does not look good in the states, if you can't lower the cost
as small molecule generic drugs, not profitable at all.
The only place for "biosimilar" is pr... 阅读全帖 |
|
a*****v
发帖数: 128 | 20 which companies are promising in this field? |
|
j*e
发帖数: 392 | 21 已经火了好一阵子了 Genentech Amgen regeneron etc. |
|
|
d***e
发帖数: 1215 | 23 如果你指的是会操作mAb的那套常用分析方法再加上做些validation啥的,半年是more
than enough.但要做到精通各种细节,还能多快好省地解决各种未知疑难问题,那就看悟
性了,悟性好又好学的半年一年可以成专家,悟性差的做二十年也还是只有照SOP操作的
水平. |
|
m*********3
发帖数: 1425 | 24 你说的都对，不过这些是senior scientist的要求，也如你说的，这些人都是骨干，不
轻易走的，entry level得话会操作mAb的那套常用分析方法再加上做些validation估计
就够了，不过现在的问题是公司招人写的是entry level,要的确是senior scientist的
水平，公司现在都很功利，就不打算培养新人，所以现在找工作的新人难，招人的也大
喊找不到。俺自己去年面了两个大药厂的onsite,都没拿到，都是经验不足，只能在现
在的小公司当个临时工，要是干完这临时工还找不到，我就不干质谱，转行干点别的，
不多说了，说多了都是泪。 |
|
l****n
发帖数: 711 | 25 1. GluC 和AspN比较常用，pepsin,chymo的特异性比较差。coverage是看confident
level的，和你怎么搜关系非常大。看看semi-enzymatic加了没，glycan搜出来没
2.找找blind modification search的软件。。。类似mascot error tolerance search
。说实话能公开找到的都不怎么好用。一般公司内部会有自己的软件或解决方法的 |
|
i**********t
发帖数: 138 | 26 are you doing HDX? then why use pepsin? chymo is fine in specificity. |
|
E***n
发帖数: 308 | 27 Do you have discover search? Remember, it is a good practice to do it
manually in the beginning. Good luck |
|
h*****t
发帖数: 1226 | 28 严重同意。
没有自己一张张谱看下来， 经验涨不了。。。。 |
|
l****n
发帖数: 711 | 29 1. GluC 和AspN比较常用，pepsin,chymo的特异性比较差。coverage是看confident
level的，和你怎么搜关系非常大。看看semi-enzymatic加了没，glycan搜出来没
2.找找blind modification search的软件。。。类似mascot error tolerance search
。说实话能公开找到的都不怎么好用。一般公司内部会有自己的软件或解决方法的 |
|
i**********t
发帖数: 138 | 30 are you doing HDX? then why use pepsin? chymo is fine in specificity. |
|
E***n
发帖数: 308 | 31 Do you have discover search? Remember, it is a good practice to do it
manually in the beginning. Good luck |
|
h*****t
发帖数: 1226 | 32 严重同意。
没有自己一张张谱看下来， 经验涨不了。。。。 |
|
f*********e
发帖数: 1144 | 33 The reason for the whole conjugate to get internalized is to get the drug
into the tumor cell which expressed the receptor biomarker. You need the mAb
to be the carrier and stay long enough for a good PK profile.
Well, I am not 100% sure. I am not a biologist, I am in process dev.
Maybe others who are expert on this can make a comment. |
|
f*********e
发帖数: 1144 | 34 The reason for the whole conjugate to get internalized is to get the drug
into the tumor cell which expressed the receptor biomarker. You need the mAb
to be the carrier and stay long enough for a good PK profile.
Well, I am not 100% sure. I am not a biologist, I am in process dev.
Maybe others who are expert on this can make a comment. |
|
|
|
d***e
发帖数: 1215 | 37 其它的不知道,但是IdeS比papain的specificity好得多
glycopeptide |
|
E***n
发帖数: 308 | 38
1, Papain first, get the intact mass of Fab?
2, Peptide mapping can help you for sure.
answer.
glycopeptide
cleavage. I always use strong acid hydrolysis.
ETD could be best here, then CID.
For small molecule , people also use PQD and HCD.
bao zi....... |
|
m*********3
发帖数: 1425 | 39 I tried ETD for glycopeptide, but the peptide signal is very low and
difficult to analyze, how about HCD/CID? |
|
h*****t
发帖数: 1226 | 40 If your glycopeitide signal is low in MS level, you need improve the
recovery
first. MS/MS by HCD/CID won't help you to determine the modification site. |
|
h*****t
发帖数: 1226 | 41 Not about analysis, but if Fab has N-link glycan, if it is not required
for activity,try to mutant the sequence and remove it . It will help you
in the future development.
glycopeptide |
|
m*********3
发帖数: 1425 | 42 not MS signal, the MS/MS signal from ETD is low. |
|
m*********3
发帖数: 1425 | 43 Sometimes, Fab N-glycan is important for activity. Indeed, Cetuximab has two
N-glycosylation sites. Furthermore, other glycoprotein such as EPO has
three N-glycosylation and one O-glycosylation, you can't just mutate the
sequence and remove all of them. |
|
b****u
发帖数: 2771 | 44 你的glycopeptide 有多少charge,
还有 啥仪器ETD，waters的话 hehe good luck. |
|
b****u
发帖数: 2771 | 45
glycopeptide
做o-glycan site ID 用CID不一定不行,你用啥仪器做 |
|
b****u
发帖数: 2771 | 46
glycopeptide
这个 我已经有一个很好的方法，因为可能要patent，不能说了。
总之不一定要切糖。 |
|
O*******f
发帖数: 926 | 47 没有帮助。
你的方向还是很火的。以后向 mAb-drug-conjugate 方向发展吧。 |
|
s*********6
发帖数: 44 | 48 很可惜，刚刚连着fail了两个onsite interview. 请版上大牛给点建议，看看我哪些地
方做的不好需要改进，谢了先。
个人背景：国内本科/美国硕士（生物化工），美国大制药公司6年工作经验（
mammalian cell culture process development），然后辞职读博士（生医工程, cell
and tissue culture, cell therapy）刚毕业。公司经验，学校文章，为人性格等都
不错，没有明显硬伤。没有身份问题。
面试职位：Senior scientist/engineer，upstream cell culture process
development，mab production
面试过程：1小时presentation, 6-10 one-to-one or group interview.
Presentation 讲了在公司和学校的研发， 50/50，4个课题。 个人Interview 总的说
感觉不错，相谈甚欢。
面试反馈：great candidate but…
药厂1：Presentation 课题太多缺少技术细节... 阅读全帖 |
|
m*********3
发帖数: 1425 | 49 刚开始找工作，请问药厂招聘cover letter有人看吗？另外版上如果有什么LC-MS的
opening能否推荐一下，我在一个biotech干了两年博士后，没有机会转正，所以开始找
工作了，有卡，主要做protein（包括mAb) PTM analysis。谢谢各位了。 |
|
b******8
发帖数: 1251 | 50 他们有个MAB-PHARM.D PROGRAM，所以才有个BUSINESS的教授，但是我不是申请这个
PROGRAM的 |
|
